(NASDAQ:OTLK) ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that a Type A Meeting request has been submitted to the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated August 27, 2025 regarding the biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD.
Related Questions
What is the expected timeline for a regulatory decision following the Type A meeting and CRL response?
How might the FDA's feedback on ONS-5010 affect Outlook Therapeutics' cash runway and need for additional financing?
What impact could the outcome of the BLA resubmission have on OTLK's valuation relative to other bevacizumabābased ophthalmic competitors?